In Section C, members will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disorder progression or even the participants are unable to tolerate the study drugs. For all movement cytometry experiments, 10,000 cells for each replicate ended up https://rogerc197jxk9.blogvivi.com/profile